Edwards Lifesciences
Gary I. Sorsher was appointed vice president, quality and regulatory compliance, in June 2020. Sorsher joined Edwards in 2015 as vice president, quality, for the early transcatheter mitral valve therapies organization. He later was appointed to a new role as vice president of quality for the valve network, and was the key quality partner to the Surgical Structural Heart leadership team. Most recently, Gary was the vice president of quality responsible for Transcatheter Mitral and Tricuspid Therapies (TMTT), advanced technology (AT), quality laboratories and pilot operations. Prior to joining Edwards, Sorsher was vice president of corporate quality compliance and medical device operations at Allergan, Inc., with responsibility for U.S. and international device facilities. Previously, Sorsher held quality leadership roles at Endologix, Inc., C.R. Bard, Inc., and Cordis, Johnson & Johnson. He received bachelor’s and master’s degrees in electrical engineering from Byelorussian Polytechnic Institute, Minsk, USSR.
Edwards Lifesciences
42 followers
Edwards Lifesciences (NYSE: EW), is the global leader of patient-focused medical innovations for structural heart disease and critical care monitoring.